The efficacy of many cancer treatments is due to their ability to induce apoptosis. DR5 can activate apoptosis pathway after binding with its natural ligand, tumour necrosis factor-related apoptosis-inducing ligand (TRAIL/ Apo2L). Both TRAIL and agonistic anti-DR5 monoclonal antibody are currently being explored for cancer therapy. The mechanisms of cytotoxicity of our previously prepared monoclonal antibody A6 against DR5 were investigated here. A6 could cause viability loss of Jurkat cells in both time-and dose-dependent manner which could be attributed to the activation of apoptosis pathway. 
Introduction
Tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL), a type II transmembrane protein, is a new member of the TNF superfamily (1) . In humans, TRAIL binds to two death-inducing receptors, DR4/TRAIL-R1 and DR5/TRAIL-R2/KILLER. TRAIL has also been shown to bind three decoy receptors, DcR1/TRID/TRAIL-R3, DcR2/ TRAIL-R4 and a soluble receptor osteoprotegerin (OPG) that was originally identified as a receptor for OPGL/RANKL (2) . The soluble form of TRAIL exhibits apoptotic activity for various cancer cell lines with minimal cytotoxicity toward normal tissues both in vitro and in vivo (1, 3) . Notable exceptions are immature human and mouse dendritic cells (DCs) that are sensitive to TRAIL-mediated apoptosis in vitro (4, 5) . Some kinds of TRAIL show cytotoxicity to normal cells. Jo et al. reported that polyhistidine tagged recombinant human TRAIL has been shown to induce apoptosis in normal human hepatocytes (6) . Other groups have also reported that recombinant human leucine zipper (LZ) and polyhistidine tagged TRAIL demonstrated apoptosisinducing ability in normal keratinocytes (7, 8) . Furthermore, the application of sTRAIL in cancer therapy is limited by its short half-life in vivo (9) .
In order to overcome the defects of TRAIL as a possible cancer therapeutic agent, numerous agonistic antibodies against DR4 or DR5 are currently being explored for cancer therapy. HGS-ETR1 is an agonistic antibody to DR4 (10) , whereas HGS-ETR2 (11), HGS-TR2J and TRA-8 (12) (13) (14) are agonistic antibodies to DR5. Compared to HGS-ETR2, HGS-TR2J seems to be a more potent DR5 antibody, because it is more effective at inducing tumour regression in xenograft models. Whereas HGS-ETR2 needs cross-linking reagents for exertion of its apoptotic activity, HGS-TR2J induces apoptosis independently of cross-linking reagents, and is therefore capable of directly activating the apoptotic pathway (2) .
We prepared an agonistic anti-DR5 antibody A6 previously which could cause viability loss without using cross-linking reagents and could not compete with TRAIL to bind DR5. In the present study, the detailed function of A6 was investigated and the intracellular molecular mechanism of A6-mediated apoptosis was studied primarily.
Materials and Methods

Cell lines and reagents
Jurkat cells (ATCC) were cultured with RPMI 1640 (Gibco) supplemented with 10% fetal bovine serum (FBS, Gibco) and maintained at 37°C in 5% CO 2 . Z-VAD-FMK, Z-LEHD-FMK, Z-IETD-FMK, anti-caspase 8 antibody and anti-caspase 9 antibody were purchased from Medical & Biological Laboratories (Japan). Antibodies against β-actin and capase 3 were purchased from Santa Cruz Biotechnology. Horse radish peroxidase-conjugated secondary antibodies were obtained from Jackson Immunoresearch Laboratories.
Binding-competition studies ELISA binding-competition studies were performed to see whether the binding epitope of A6 was similar to that of TRAIL (15) . Briefly, polystyrene plates were coated with 2 μg/ml purified DR5 in 0.05 M bicarbonate buffer (pH 9.6) at 37°C for 1 h and blocked with 10% FBS/PBS for 1 h at 37°C. A6 mAbs (11 pmol/ml) were mixed with an equal volume of TRAIL in serial dilutions (0.67, 2.01, 6.05, 18.15, 54.47 and 163.41 pmol/ml) and 100 μl of the mixture was added to the plate and then incubated at 37°C for 1 h. After washing with PBST, GAM-HRP (horseradish peroxidase conjugated goat anti-mouse antibody, 0.1 μg/ml) was added and incubated at 37°C for 1 h. After washing again with PBST, 5.5 mM o-phenylenediamine hydrochloride and 8.5 mM H 2 O 2 were added. The reaction was terminated by 1 M H 2 SO 4 . The absorbance was measured chromatically at 492 nm with an ELISA-reader (Anthos, Austria) (16) .
Cytotoxicity assay
The cytotoxicity was measured using MTT assays. Target cells (90 μl) were dispensed into 96-well cell culture plate at 8.9 × 10 5 /ml. Samples (10 μl) were added to each well in triplicate. The plates were kept in incubator at 37°C, 5% CO 2 for designed time. About 10 μl MTT (10 mg/ml) was added. The plates were incubated for additional 4 h at 37°C. Following this incubation, 100 μl solubilization solution was added and incubated at 37°C for another 12 h. The plate was then read at 570 nm using a plate reader.
Apoptosis analyses
Annexin V was used to detect early stage apoptosis. Cells were resuspended at a concentration of 8.9 × 10 5 cells/ml in RPMI containing 10% FBS, 4 mM L-glutamine and 1% Pen-Strep in a 24-well dish, and treated with various samples. After incubated for indicated time, cells were harvested for analysis using Annexin V-FITC apoptosis detection kit according to the vendor's protocol. The cells were analyzed on a FACSCalibur flow cytometer (Becton Dickinson, San Jose, Calif. USA).
Cell lysate preparation
The cultured cells were harvested, washed with PBS, and lysed in a lysis buffer [1% Triton-100, 150 mmol/L NaCl, 10 mmol/L Tris (pH 7.4), 1 mmol/L EDTA, 1 mmol/L EGTA (pH 8), 0.2 mmol/L sodium orthovanadate, 0.2 mmol/L phenylmethylsulfonyl fluoride, 0.5% NP40, 0.1% SDS] for 30 minutes at 4°C with constant agitation. The cell lysate was then centrifuged (16,000 g at 4°C) for 15 minutes to remove insoluble materials. The protein concentrations of supernatants were measured by Lowery assay (17) .
Western blotting
Protein samples were electrophoresed in 15% SDS-PAGE and transferred to a nitrocellulose membrane with a horizontal electrophoretic transfer system (Bio-Rad, USA). The membrane was blocked with 5% skim milk and then probed with appropriate primary antibody followed by reaction with horseradish peroxidase-conjugated secondary antibody. Blot was developed using the enhanced chemiluminesens (ECL) reagents and recorded on an X-ray film (18, 19) .
Statistical analysis
Statistical differences were analysed using the prism 5 software. The p value of < 0.05 was considered to be statistically significant. All data were expressed as mean ± SEM.
Results
The binding activity of A6 and TRAIL were non-competitive Currently, several anti-DR5 antibodies are under development to be used in clinical settings. The epitope is a key characteristic of an antibody. Ichikawa et al. had prepared an anti-DR5 mAb TRA-8 which efficiently competed with TRAIL for binding to DR5, indicating that TRA-8 might recognize an epitope within the TRAIL-binding site on DR5 (13) . TRA-8 could induce apoptosis of most TRAIL-sensitive tumor cells in the absence of the secondary cross-linking. TRA-8 also exhibited strong tumoricidal activity in vivo (13) . Competitive ELISA results suggested that A6 could not compete with TRAIL for binding to DR5 (Figure 1) , demonstrating that the epitope recognized by A6 is different from the TRAIL-binding site on DR5.
The cytotoxicity of agonistic mAb A6 to Jurkat cells DR5 is death receptor of TRAIL with a death domain (DD) and a death effect domain (DED) in its intracellular fragment. After binding with its natural ligand TRAIL, DR5 is capable of transducing an apoptotic signal and results in cell death. To be a potential therapeutic agent, antibody against DR5 should be able to kill tumor cells by activating DR5 mediated (Figure 2A ). TRAIL could also kill target cells in the same manner. The EC 50 (50% effective concentration) of A6 incubated with tumor cells for 24 h was also similar to that of TRAIL ( Figure 2B ).
Inducing apoptosis was one of the cytotoxicity mechanisms of A6
The efficacy of many cancer treatments including radiotherapy, chemotherapy and immunotherapy is due to their ability to induce tumor cell apoptosis. TRAIL is being developed as an anti-cancer therapeutic agent. Next we wanted to know if A6 could act in the same way as TRAIL. After 50 and 100 min incubation, both A6 and TRAIL induced significant apoptosis of Jurkat cells. The ratio of apoptosis induced by TRAIL was higher than that of A6 at the two time points (Figure 3 ).
Caspases were involved in A6 induced apoptosis
Jurkat cells were treated with A6 for indicated time and cell lysate was prepared as described in Materials and Methods.
After detection with specific antibodies against caspase 8, caspase 9 and caspase 3 by using Western bloting, we found that all of the three apoptosis related caspases were activated in Jurkat cells treated with A6 in a time-dependent manner. The active fragments of caspase 8 and caspase 9 could be detected after 60 to 120 min incubation with A6. Decreased amount of procaspase 3 could also be detected, especially after 120 min incubation with agonistic anti-DR5 antibody A6. TRAIL could activate the three caspases in almost the same way with A6 ( Figure 4 ).
The apoptosis induced by A6 was caspase-dependent
Death receptors can activate both "cell-intrinsic" and "cellextrinsic" pathways to induce target cell death. Whatever the Jurkat cells were treated with A6 (10 pmol/ml) and TRAIL (10 pmol/ml) for 15, 30, 60 and 120 min and intracellular activation of caspase 8, caspase 9 and caspase 3 was detected by using Western blotting methods. β-actin was used as a loading control.
pathway is, caspases seem indispensable. But caspaseindependent apoptosis does exist (20) . Here, Z-VAD-FMK (a broad spectrum of caspase inhibitor), Z-LEHD-FMK (a caspase 9 specific inhibitor) and Z-IETD-FMK (a caspase 8 specific inhibitor) were used to study if A6 mediated cell apoptosis was caspase dependent or not. Cells were pretreated with caspase inhibitor for 40 min before the agonistic antibody A6 was added. The results of MTT assay demonstrated that all the three caspase inhibitors could make the cytotoxicity curve of A6 move to the right, suggesting that the caspase inhibitor could reduce the cytotoxicity of A6 to Jurkat cells with Z-VAD-FMK displaying the most inhibition ability. Capase inhibitors could also inhibit the cytotoxicity of TRAIL, acting in the similar style to A6 cytotoxicity ( Figures 5A, 5B ).
To further testify whether the apoptosis of Jurkat cells induced by A6 was caspase-dependent, Annexin V-FITC and PI double staining was used to evaluate inhibition effect of caspase inhibitors to the apoptosis of Jurkat cells induced by A6. Jurkat cells were incubated with A6 for 100 min after 40 min pretreatment with caspase inhibitors allowing sufficient engulfment of the inhibitors. Apparently, both broad spectrum caspase inhibitor and caspase 9 specific inhibitor could decrease the apoptosis level induced by A6 and TRAIL ( Figure 5C ).
In conclusion, both A6 and TRAIL could kill Jurkat cells. This kind of cytotoxicity was due to the activation of caspase-dependent apoptosis.
Discussion
From the crystallization structure of TRAIL-DR5 complex, we found that TRAIL could recognize two epitopes presented on the surface of DR5 antigen. Agonistic antibody TRA-8 might recognize an epitope within the TRAIL-binding site as it was demonstrated in the study of Ichikawa et al. (13) and by computer aided analysis (our unpublished data). Our experiment results suggested that A6 could not compete TRAIL's binding to DR5, which indicated that A6 and TRAIL bound to a different epitope on DR5, raising the possibility that A6 and TRAIL may trigger different downstream cell signals. So, we focused on the research of the detail characteristic of A6, especially signal transduction pathway mediated by A6. Both A6 and TRAIL could kill target cells in both time-and dose-dependent manners. The cytotoxicity of A6 was due to its apoptosis inducing ability, and caspase activation, such as caspase 3, caspase 8 and caspase 9. Caspase specific inhibitor could counteract A6 mediated cell viability loss and apoptosis which suggested that the cytotoxicity of A6 was caspase-dependent. In Jurkat cells, caspases 8, 9, and 3 were activated by TRAIL treatment which has been described before (21) . In conclusion, TRAIL and agonistic mAb against DR5 with different binding epitopes recognized by TRAIL, could induce similar molecular events in Jurkat cells. Caspase 9 was activated in cell-intrinsic pathway and active caspase 9 fragments were detected in the lysate of Jurkat cells treated with A6 or TRAIL. In type I cells, cell-extrinsic pathway was activated. Upon activation, DR5 trimerizes allowing clustering of the DD located within the cytoplasmic regions and formation of the death-inducing signaling complex (DISC) followed by activation of caspase 8. This leads to proteolytic activation of executioner caspases such as caspase 3 and ultimately to death of the target cells (22) . So no active caspase 9 can be detected in type I cells. But in type II cells, cross-talking between cell-extrinsic pathway and cell-intrinsic exists. Mitochondria-mediated apoptosis pathway was activated and then procaspase 9 was activated in apoptosome. And then, the active caspase 9 activated executioner caspases leading to target cell death (22) . Both A6 and TRAIL could activate not only caspase 8 and caspase 3, but also caspase 9. Therefore, Jurkat cells are a type II cell line. And both A6 and TRAIL induced target cells death through crosstalking between 'cell-intrinsic' and 'cell-extrinsic' pathways.
In conclusion, the agonistic antibody A6 could cause viability loss of TRAIL-sensitive Jurkat cells by inducing apoptosis in which caspase activation was involved. A6 inducted apoptosis was similar to that of TRAIL in Jurkat cells. Based on the results of present study, A6 may be a potential clinical immunotherapy candidate. The differences of apoptosis pathway between A6 and TRAIL in other tumor cell lines are under investigation and will be reported in future work.
